Ireland's HSE to decide on reimbursement for €280k-a-year Friedreich's ataxia drug Skyclarys

The Irish Health Service Executive (HSE) is scheduled to finalize a decision on the public funding of Skyclarys, a high-cost treatment for the rare genetic disorder Friedreich's ataxia. The outcome remains uncertain following high-level political engagement between the Taoiseach and affected families, highlighting the tension between fiscal constraints and patient access to orphan drugs.